TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02676492

Intervention type: OTHER
Intervention: Actigraphy to measure sleep duration and efficiency
Description: Actigraphy watch to be worn on participants' wrist for 14 days and nights

Intervention type: OTHER
Intervention: Actigraphy to measure sleep duration and efficiency
Description: Actigraphy watch to be worn on participants' wrist for 14 days and nights
Study: NCT02223377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
Study: NCT00942526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycostatin oral suspension
Description: peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water
Description: perioperative gargling with water
Study: NCT02676492

Intervention type: OTHER
Intervention: 'Sleepsuite' novel cognitive learning tasks
Description: Novel iPad-administered learning tasks, to be completed one evening and the next morning during actigraphy monitoring period.

Intervention type: OTHER
Intervention: 'Sleepsuite' novel cognitive learning tasks
Description: Novel iPad-administered learning tasks, to be completed one evening and the next morning during actigraphy monitoring period.
Study: NCT00846963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol
Description: Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (\>33mmol/L) to the resolution of cholestasis (conjugated bilirubin \<34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.~If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given.
Study: NCT03155581

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: User intervention
Description: To make participants aware of the lack of participation in screening programs and its consequences, and help to manage obstacles to participation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health professional intervention
Description: To provide information on the low attendance of migrants to cervical cancer screening and tools to improve the situation
Study: NCT03910829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Action observation training
Study: NCT00548327

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
Study: NCT02314546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Study participants will be randomly assigned to one of three treatment groups:~* Group 1 - Placebo - Control patients will receive intranasal saline.~* Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.~* Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Study participants will be randomly assigned to one of three treatment groups:~* Group 1 - Placebo - Control patients will receive intranasal saline.~* Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.~* Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
Study: NCT03910829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Motor imagery protocol
Study: NCT00846963

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo given in the same amount that ursodiol would be given, depending on enteral feeding and weight. It is also given three times a day, until cholestasis resolution.
Study: NCT03910829

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Action Observation
Description: Placebo Action Observation
Study: NCT03798964

Intervention type: OTHER
Intervention: Placental analysis
Description: Analysis of placenta to determine expression of heparanase

Intervention type: OTHER
Intervention: Placental analysis
Description: Analysis of placenta to determine expression of heparanase

Intervention type: OTHER
Intervention: Placental analysis
Description: Analysis of placenta to determine expression of heparanase
Study: NCT02783703

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium chain triglycerides (MCT)
Description: Subjects will consume 30 grams per 2000 kilocalories daily of medium chain triglyceride oil by mouth
Study: NCT02616289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical emollient (Sun Flower seed oil)
Description: 3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.
Study: NCT03882814

Intervention type: DRUG
Intervention: pethidine
Description: Pethidine 50 mg intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. Opioid analgesia (pethidine HCl - 50 mg I.M.) was given following amniotomy.

Intervention type: DRUG
Intervention: Placebo - Concentrate
Description: Intramuscular saline was administered to the control group as placebo. Salin intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. salon was given following amniotomy.
Study: NCT02915523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entinostat
Description: An orally available histone deacetylases inhibitor (HDACi).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: avelumab
Description: A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: avelumab
Description: A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pill containing no active drug ingredient.
Study: NCT03940859

Intervention type: DEVICE
Intervention: intracranial stent, flow diverter and coils
Description: Endovascular treatment was performed under general anesthesia. Patients were treated with internal trapping, stent-assisted coiling or flow diverter as appropriate. After the procedure, patients treated with conventional stent were given 75mg/d clopidogrel for 6 weeks and 100mg/d aspirin for 6months, while patients treated with flow diverter were given 75mg/d clopidogrel for 3 months and 100mg/d aspirin thereafter. All patients were recommended to undergo a 6-month angiographic follow-up.
Study: NCT01685463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Active TMS:1 Hz, 100% motor threshold TMS for 15 minutes, total 900 pulses. Electrical stimulation instead.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS. The sham-TMS scalp discomfort will be matched to that of active TMS.
Study: NCT03884738

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concentric Exercise
Description: Leg Curl Machine: 1st week - 1st day is 10 maximum repeat test. 2nd week - 2 days of training - 2 sets of 6 repeats. %60 percent of maximum load.~3rd week - 3 days of training - 3 sets of 6-8 repeats. %60-80 of maximum load. 4th-8th week - 3 days of training - 3 sets of 8-12 repeats. when 3 sets of 12 achieved, load was increased with 2.5kg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic Eccentric exercise
Description: 1. st week - 1 day - 2 sets of 5 repeats.~2. nd week - 2 days - 2 sets of 6 repeats.~3. rd week - 3 days - 3 sets of 6-8 repeats.~4. th week - 3 days - 3 sets of 8-10 repeats. 5-8th weeks - 3 days - 3 sets of 12-8 repeats. When achieved 3 sets of 12 repeats with full range, speed was increased.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation
Description: 8 weeks, three times per week, 15 minutes of bilateral hamstring stimulation. 100 Hz. frequency, 600 microsecond duration rectangular current
Study: NCT02713958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Telerehabilitation: Telerehabilitation treatment using a computerized system (MediTouch) for improving the elbow motion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Traditional Occupational Therapy treatment: Active exercises for elbow motion
Study: NCT00123006

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Approaches to Stop Hypertension (DASH)
Description: 4 week feeding intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Diet
Description: 4 week feeding intervention
Study: NCT03927001

Intervention type: DEVICE
Group type: OTHER
Intervention: NeVa Stent Retrievers
Description: mechanical neurothrombectomy
Study: NCT03326076

Intervention type: DIAGNOSTIC_TEST
Intervention: Donor-derived cell-free DNA (AlloSure®)
Description: Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.

Intervention type: DIAGNOSTIC_TEST
Intervention: Donor-derived cell-free DNA (AlloSure®)
Description: Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.

Intervention type: DIAGNOSTIC_TEST
Intervention: Donor-derived cell-free DNA (AlloSure®)
Description: Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.

Intervention type: DIAGNOSTIC_TEST
Intervention: Donor-derived cell-free DNA (AlloSure®)
Description: Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.

Intervention type: OTHER
Intervention: Standard care
Description: Current standard methods for monitoring of renal allograft recipients for rejection (e.g. donor-specific antibodies, serum creatinine, proteinuria, renal allograft biopsy)

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood gene expression profiling (AlloMap Kidney)
Description: Patients will receive peripheral blood gene expression profiling testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood gene expression profiling (AlloMap Kidney)
Description: Patients will receive peripheral blood gene expression profiling testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analytic platform (IBox)
Description: Patients will receive IBox testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analytic platform (IBox)
Description: Patients will receive IBox testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
Study: NCT00535132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Risperidone
Description: 4 or 6 mg MG once daily for 0-2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 6, 9 or 12 MG once daily for 4-6 weeks
Study: NCT03488875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mMBRT
Description: Madison Mindfulness-Based Resilience Training (mMBRT) is an 8-week mindfulness-based intervention developed specifically for police officers, which is similar to and inspired by a program developed by researchers at Pacific (OR) University (Christopher, Goerling et al., 2016). mMBRT includes 8 weekly 2-hour classes involving guided meditation practice, gentle movement, and group-based discussion (the 7th class is a longer, 4-hour class). The total class time is about 18 hours over 8 weeks, and participants are asked to engage in home practice for up to 30 minutes/day, 6 days/week throughout the intervention.
Study: NCT01674101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance
Description: Endurance exercise will consist of ambulating with assistive devices as needed, upper extremity (UE) ergometer, and/or playing the Wii.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening
Description: Strengthening exercises will involve both UE's and LE's. For UE's, bicep curls, triceps curls, shoulder flexion, and/or press-ups from the therapy mat or wheelchair will be included. For the LE's, bridging, long arc quads, hamstring curls, calf raises in standing, single LE squats, and/or dorsiflexion (DF) in supine will be performed on the uninvolved extremity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching will consist of ankle stretch into DF in supine or long sitting, hamstring stretch in supine with hip flexed to 90 degrees, and trunk extension in sitting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: All participants will be given a tailored home exercise program (HEP) including endurance exercises, strengthening, and stretching exercises to be completed on days they do not have PT. If the participants return home, they will be asked to complete the HEP at least 3 days per week. The physical therapist will contact the participant weekly to modify the HEP if necessary and determine compliance.
Study: NCT02956551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: subcutaneous administration
Study: NCT02766738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GrACE program
Description: to compare with the GrACE + gait programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GrACE + gait
Description: to compare with the GrACE programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
Study: NCT00729456

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
Study: NCT02389127

Intervention type: DEVICE
Intervention: Continuous glucose monitor (Dexcom, San Diego, CA)
Description: (Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (Dexcom, San Diego, CA) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks.

Intervention type: DEVICE
Intervention: Continuous glucose monitor (Dexcom, San Diego, CA)
Description: (Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (Dexcom, San Diego, CA) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks.
Study: NCT02246062

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: info
Description: the relative received leaflet containing information about the anesthetic procedure one day before the surgery at ward.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: info
Description: the relative received leaflet containing information about the anesthetic procedure one day before the surgery at ward.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smartphone
Description: the child received smartphone application immediately before entering the operating room

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smartphone
Description: the child received smartphone application immediately before entering the operating room
Study: NCT02919436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose-filled capsules identical to active drug
Study: NCT03130244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnet Anastomosis System
Description: The MAS will be placed using an endoscope in the duodenum and and laparoscopically into ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the duodenum to ileum treats Type 2 diabetes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Management
Description: The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.
Study: NCT04718974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth call for life system/ tool using IVR ( interactive voice response)
Description: The tool capitalises on a basic mobile phone's core utilities of voice and short messaging services. The system design, development, testing and evaluation was done by Janssen and the Grameen Foundation (http://motechsuite.org/index.php/implementations). In 2015, Janssen Global Public Health Research and Development, in close collaboration with the Infectious Diseases Institute Kampala (IDI), developed Call for Life Uganda (CFLU) tailored to the needs of PLHIV in Uganda
Study: NCT04435509

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1000+ Greek Mountain Tea
Description: Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams (4 grams 3 times per day ) 50 grams per month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mediterranean Diet
Description: a Mediterranean dietary protocol
Study: NCT03259074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to AIN457 150 mg dose administered with AIN457 via pre-filled syringes

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GP2017 (adalimumab biosimilar)
Description: 40 mg in pre-filled syringes was administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457 150 mg
Description: 150 mg in pre-filled syringes was administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457 150 mg
Description: 150 mg in pre-filled syringes was administered subcutaneously
Study: NCT02410135

Intervention type: DRUG
Intervention: Mirabegron
Description: 25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks
Study: NCT06126432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yugart
Description: Yugart 2 bottles per day for 1 month
Study: NCT01890603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data Collection
Description: Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
Study: NCT04550598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tCES
Description: The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 5 times a week, lasting for 2 weeks.
Study: NCT01755715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate IUD insertion
Description: Insertion of LNG-IUD (Mirena) (at the same day to 3 days) after expulsion of placenta.